US OptionsDetailed Quotes

PFE250502C22500

Watchlist

1.36
+0.55+67.90%

15min DelayClose Apr 29 16:00 ET

1.62High0.36Low

Pfizer Stock Discussion

Bildo Swaggins

5 hours ago

$Pfizer (PFE.US)$ sold all my calls. Will watch this to see if it tests 22.5 again. if it does I will be back.

Deep Sea

6 hours ago

$Pfizer (PFE.US)$
The stock finally breaks above 24. If the price can stay above 24, the uptrend momentum will be sustainable.

Deep Sea

8 hours ago

$Pfizer (PFE.US)$
Big green candle. Next resistance is 24.10. Once it breaks the resistance, next hit point will be 24.28. The stock is trading above 5 EMA, 10 EMA and 20 EMA but below 60 EMA. The trend is up and bullish.

Deep Sea

8 hours ago

$Pfizer (PFE.US)$
$Pfizer (PFE.US)$'s stock rose Tuesday after the drug manufacturer said it's trending toward the higher end of its 2025 profit projections.
Pfizer also beat analyst expectations for first-quarter earnings as it benefited from cost-saving efforts, although it fell short of Wall Street's revenue estimate, as sales of its COVID-19 medicine Paxlovid plunged by 75% on fading demand.
"Our focus on operational efficiency and financial discipline is driving strong results to our bottom l...

BC_76

13 hours ago

7 percent yield from dividends, making history.

$Pfizer (PFE.US)$ time for the bounce tonight?

105754083

Apr 28 17:32

$Pfizer (PFE.US)$ what will the financial result gonna be today?

Teddy123

Apr 28 10:51

Pfizer’s Sasanlimab Combination Significantly Improves Event-Free Survival in BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer

$Pfizer (PFE.US)$
Breakthrough: Pfizer's New Bladder Cancer Treatment First Major Advance in 30 Years - See 91% Success Rate

Deep Sea

Apr 28 10:22

$Pfizer (PFE.US)$
Pfizer (PFE) announced results from the pivotal Phase 3 CREST trial of sasanlimab, an investigational anti-PD-1 monoclonal antibody, in combination with standard of care Bacillus Calmette-Guerin as induction therapy with or without maintenance in patients with BCG-naive, high-risk non-muscle invasive bladder cancer, NMIBC. The trial met its primary endpoint of event-free survival, EFS, by investigator assessment, demonstrating a clinically meaningful and statistically significan...

搞经济抄底加仓

Apr 27 06:31

I'm just thinking if FDA, WHO, and them are together in this.. ? whatever cancer cure and other cure forever stop at 50% to 85% and they will change to another new treatment and then 50% to 85% and repeat.. seriously, is 2025 already they think we're still living in 1925 when all people don't go to school?
get done once, just once a 100%
$Johnson & Johnson (JNJ.US)$
$Pfizer (PFE.US)$
$E-mini NASDAQ 100 Futures(JUN5) (NQmain.US)$
$E-mini S&P 500 Futures(JUN5) (ESmain.US)$